AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

Technology Overview

Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections – such as pneumonia, tuberculosis, blood poisoning, gonorrhea, and foodborne diseases – are becoming harder, and sometimes impossible, to treat as antibiotics become less effective. Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill. 

WHO - World Health Organization

Antibiotic resistance will remain a major threat to public health unless alternative antimicrobial therapies are developed.

Uncontrolled AMR Threat

Armata is harnessing the power of natural and synthetic phages, converting them into life-saving pharmaceuticals, and transforming medicine.

MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant enterococci; PDR: pandrug-resistant; AMR: antimicrobial resistance. 

Learn more about the Antimicrobial Resistance crisis here »